{"organizations": [], "uuid": "76b8e4cf0bde04fa44698621dfed2ef65e0db92a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/krka-results/update-1-slovenian-drugmaker-krka-reports-16-pct-jump-in-q1-group-net-profit-idUSL5N1SU13A", "country": "US", "domain_rank": 408, "title": "UPDATE 1-Slovenian drugmaker Krka reports 16 pct jump in Q1 group net profit", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-23T15:21:00.000+03:00", "replies_count": 0, "uuid": "76b8e4cf0bde04fa44698621dfed2ef65e0db92a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/krka-results/update-1-slovenian-drugmaker-krka-reports-16-pct-jump-in-q1-group-net-profit-idUSL5N1SU13A", "ord_in_thread": 0, "title": "UPDATE 1-Slovenian drugmaker Krka reports 16 pct jump in Q1 group net profit", "locations": [], "entities": {"persons": [{"name": "louise heavens", "sentiment": "none"}, {"name": "marja novak", "sentiment": "none"}], "locations": [{"name": "ljubljana", "sentiment": "none"}, {"name": "czech republic", "sentiment": "none"}, {"name": "scandinavia", "sentiment": "none"}, {"name": "croatia", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "krka", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds details, background)\nLJUBLJANA, May 23 (Reuters) - Slovenian generic drugs producer Krka reported a 16 percent jump in first-quarter net profit to 49.4 million euros ($58.08 million) due to higher sales and cost cutting.\nSales rose by 5 percent to 338.3 million euros, while costs fell by 3 percent, the company said in a statement on Wednesday.\nIt said Scandinavia saw the highest growth of sales of its prescription drugs among Krkaâ€™s large markets with an increase of 37 percent, while the Czech Republic rose 25 percent and Croatia grew 17 percent.\nIt added total sales of prescription drugs were up by 6 percent while sales of non-prescription products increased by 11 percent.\nIt confirmed its target to achieve 2018 net profit of 153 million euros on sales of 1.3 billion euros, with sales growth of at least 5 percent each year until 2022. ($1 = 0.8505 euros) (Reporting by Marja Novak, editing by Louise Heavens)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T15:21:00.000+03:00", "crawled": "2018-05-24T20:13:16.029+03:00", "highlightTitle": ""}